Endothelial to haematopoietic transition contributes to pulmonary arterial hypertension
ConclusionEHT contributes to the pathogenesis of PAH. The transcription factor Runx1 may be a novel therapeutic target for the treatment of PAH.
Source: Cardiovascular Research - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Genetics | Heart | Hypertension | Pulmonary Hypertension | Transplants